Commercial ADA ’26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option BioPharma DiveAt a big meeting for weight loss drugs, Lilly s triple G therapy set a new standard as lingering doubts surrounded other competing treatments.Metabolic & GLP-1Read full story pharminent June 8, 2026 (Last updated: June 8, 2026) BioPharma Dive At a big meeting for weight loss drugs, Lilly s triple G therapy set a new standard as lingering doubts surrounded other competing treatments. Metabolic & GLP-1 Read full story Post navigation Previous: ADA: Boehringer leans on fat mass benefits as obesity bet delivers ‘less competitive’ weight reductionNext: J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1B Related Stories Commercial Lilly’s $23B Q2 soars over expectations but Foundayo lags Novo’s rival oral GLP-1 pharminent August 5, 2026 Commercial Leqembi sales grow again after subcutaneous approvals pharminent July 29, 2026 Commercial Wegovy pill launches in UK as first daily oral GLP1 for weight management pharminent July 6, 2026
